Cargando…
Combined cell-based therapy strategies for the treatment of Parkinson’s disease: focus on mesenchymal stromal cells
Parkinson’s disease is a neurodegenerative condition characterized by motor impairments caused by the selective loss of dopaminergic neurons in the substantia nigra. Levodopa is an effective and well-tolerated dopamine replacement agent. However, levodopa provides only symptomatic improvements, with...
Autores principales: | Rodríguez-Pallares, Jannette, García-Garrote, María, Parga, Juan A., Labandeira-García, José Luis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727452/ https://www.ncbi.nlm.nih.gov/pubmed/36018150 http://dx.doi.org/10.4103/1673-5374.350193 |
Ejemplares similares
-
Dose‐dependent effect of mesenchymal stromal cells co‐grafted with dopaminergic neurons in a Parkinson's disease rat model
por: Rodriguez‐Pallares, Jannette, et al.
Publicado: (2021) -
NRF2 Activation and Downstream Effects: Focus on Parkinson’s Disease and Brain Angiotensin
por: Parga, Juan A., et al.
Publicado: (2021) -
Data on the effect of Angiotensin II and 6-hydroxydopamine on reactive oxygen species production, antioxidant gene expression and viability of different neuronal cell lines
por: Parga, Juan A., et al.
Publicado: (2018) -
Interaction between Angiotensin Type 1, Type 2, and Mas Receptors to Regulate Adult Neurogenesis in the Brain Ventricular–Subventricular Zone
por: Garcia-Garrote, Maria, et al.
Publicado: (2019) -
Nigral Neurons Degenerating in Parkinson's Disease Express the Angiotensin Receptor Type 1 Gene
por: Labandeira‐Garcia, Jose L., et al.
Publicado: (2022)